Open Access. Powered by Scholars. Published by Universities.®
- Discipline
-
- Biochemistry (1)
- Biochemistry, Biophysics, and Structural Biology (1)
- Bioinformatics (1)
- Biomedical Informatics (1)
- Cell Biology (1)
-
- Chemistry (1)
- Environmental Health (1)
- Medicinal-Pharmaceutical Chemistry (1)
- Medicine and Health Sciences (1)
- Molecular Biology (1)
- Organic Chemistry (1)
- Other Cell and Developmental Biology (1)
- Other Pharmacy and Pharmaceutical Sciences (1)
- Pharmacology, Toxicology and Environmental Health (1)
- Pharmacy and Pharmaceutical Sciences (1)
- Physical Sciences and Mathematics (1)
- Keyword
-
- Bioinformatics (1)
- Cancer (1)
- Cancer metabolism (1)
- Chemical biology (1)
- Chemotherapy (1)
-
- Colorectal Cancer (1)
- Cytochrome P450 1B1 (1)
- DKK1 (1)
- DNA Repair (1)
- EZH2 (1)
- Enzalutamide resistance (1)
- HLTF (1)
- Immune Checkpoint Inhibitors (1)
- Immunotherapy (1)
- Inflammation (1)
- Lung cancer (1)
- Medicinal chemistry (1)
- Mismatch Repair (1)
- Neutrophils (1)
- Non-Small-Cell Lung Carcinoma (1)
- Overall Survival (1)
- Oxidative Stress (1)
- Peroxiredoxin (1)
- Phosphorylation-mediated degradation (1)
- Polo-like kinase 1 (1)
- Post-Replicative Repair (1)
- Programmed Cell Death 1 Receptor (1)
- Programmed cell death 4 (1)
- Pyruvate dehydrogenase subunit E1 alpha (1)
- Rad5 (1)
Articles 1 - 6 of 6
Full-Text Articles in Cancer Biology
Understanding The Role Of Peroxiredoxin Iv In Colorectal Cancer Development, Pratik Thapa
Understanding The Role Of Peroxiredoxin Iv In Colorectal Cancer Development, Pratik Thapa
Theses and Dissertations--Toxicology and Cancer Biology
Reactive oxygen species (ROS) are oxygen-containing free radicals and/or molecules that are more reactive than O2. ROS such as hydroxyl radical (•OH) and hydrogen peroxide (H2O2) are produced naturally in the body as a result of reactions such as aerobic respiration and oxidative protein folding. ROS undergo reduction-oxidation (redox) reactions and mediate cell signaling. Accumulation of excessive ROS can damage DNA, RNA, protein and lipids. Antioxidants are enzymes and small molecules that react with ROS to modulate redox signaling and to prevent and repair oxidative damage. Examples of antioxidants include glutathione, thioredoxin, superoxide dismutase, …
Conserved Novel Interactions Between Post-Replicative Repair And Mismatch Repair Proteins Have Differential Effects On Dna Repair Pathways, Anna K. Miller
Conserved Novel Interactions Between Post-Replicative Repair And Mismatch Repair Proteins Have Differential Effects On Dna Repair Pathways, Anna K. Miller
Theses and Dissertations--Toxicology and Cancer Biology
DNA mismatch repair (MMR) is the DNA repair mechanism that repairs base-base mispairs and small insertions and deletions remaining after replication. MMR is also required for apoptosis after certain types of exogenous DNA damage that result in damage-associated mispairs. The basic MMR mechanism is well understood; however, proteins associated with MMR continue to be identified. The roles of these interacting proteins in MMR are largely unknown. We have identified the yeast protein Rad5 as a novel interactor of the critical MMR proteins Msh2 and Mlh1. Rad5 is a DNA helicase and E3 ubiquitin ligase involved in post-replicative repair. However, to …
Beyond Mitosis, Plk1-Mediated Phosphorylation Re-Wires Cancer Metabolism And Promotes Cancer Progression, Qiongsi Zhang
Beyond Mitosis, Plk1-Mediated Phosphorylation Re-Wires Cancer Metabolism And Promotes Cancer Progression, Qiongsi Zhang
Theses and Dissertations--Toxicology and Cancer Biology
Polo-like kinase 1 (PLK1) is a well- characterized regulator of cell division and is known to be highly expressed in certain types of tumors. It has been demonstrated the multifaceted roles of PLK1 in regulation of transcription, translation, epigenetics, DNA damage and cellular metabolism et al. Despite these findings, the precise mechanisms by which PLK1 regulates these processes beyond mitosis remain unclear. PLK1-mediated phosphorylation and misregulation of its substrates has been linked to tumorigenesis, cancer progression, drug resistance and worse prognosis. In this study, we investigated the non-canonical functions of PLK1 in cancer metabolism and drug resistance. We found that …
Development And Biological Evaluation Of Selective Small-Molecule Inhibitors Of The Human Cytochrome P450 1b1, Austin Hachey
Development And Biological Evaluation Of Selective Small-Molecule Inhibitors Of The Human Cytochrome P450 1b1, Austin Hachey
Theses and Dissertations--Chemistry
The human cytochrome P450 1B1 (CYP1B1) is an emerging target for small- molecule therapeutics. Several solid tumors overexpress CYP1B1 to the degree that it has been referred to as a universal tumor antigen. Conversely, its expression is low in healthy tissues. CYP1B1 may drive tumorigenesis through promoting the formation of reactive toxins from environmental pollutants or from endogenous hormone substrates. Additionally, the expression of CYP1B1 in tumors is associated with resistance to several common chemotherapies and with poor prognoses in cancer patients. However, inhibiting CYP1B1 with small molecules has been demonstrated in cellular and murine model systems to reverse this …
Targeting Ezh2 To Improve Outcomes Of Lung Squamous Cell Carcinoma, Tanner Ducote
Targeting Ezh2 To Improve Outcomes Of Lung Squamous Cell Carcinoma, Tanner Ducote
Theses and Dissertations--Toxicology and Cancer Biology
Only 20% of patients diagnosed with lung squamous cell carcinoma (LSCC) respond to immunotherapy. Anti-PD1 immunotherapy is most commonly prescribed to these patients; however, most will become refractory. It is important to understand the mechanisms underlying this problem to increase durability and survival. Building upon the work of other groups, our lab has demonstrated that the inhibition of the histone methyltransferase, EZH2, is crucial to maintaining an immunologically responsive microenvironment. Based on our data, we hypothesize that combining EZH2 inhibitors with anti-PD1 therapy will increase response and durability. To study non-small cell lung cancers (NSLC) our lab uses a variety …
Bioinformatic Analysis Of Proteomic And Genomic Data From Nsclc Tumors On Prognostic And Predictive Factors Of Immunotherapy Treatment, Mark Wuenschel
Bioinformatic Analysis Of Proteomic And Genomic Data From Nsclc Tumors On Prognostic And Predictive Factors Of Immunotherapy Treatment, Mark Wuenschel
Theses and Dissertations--Pharmacy
Recent lung cancer research has led to advancements in molecular immunology, resulting in development of small molecule inhibitors, or immune checkpoint inhibitors, that propagate an anti-tumor T cell response. Despite increased overall and progression-free survival with reduced adverse effects compared to traditional chemotherapy, treating advanced stage lung adenocarcinoma patients remains non-curative, and evidence of non-responders or tumor recurrence to immune checkpoint inhibitor therapy is growing. Also, compared to traditional chemotherapy, there is a lower percentage of patients who respond to small molecule inhibitors. In this analysis of proteomic and genomic data from The Cancer Proteome Atlas and Global Data Commons …